Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.” 

Goldman Sachs & Co. LLC, Citigroup and Guggenheim Securities acted as joint book-running managers for the offering. LifeSci Capital and Oppenheimer & Co. acted as lead managers, and B. Riley Securities, H.C. Wainwright & Co., and Jones acted as co-managers for the offering. 

The Mintz team included Securities & Capital Markets Practice Co-chair John Rudy, Member Nishant Dharia, and Associates Samantha Silver, Gianna Nappi, Gretchen Goyette, Jocelyn Sun, and Patricia Garza Gonzalez. 

More information about the transaction is available here.